Randomized phase 2 trial of neoadjuvant palbociclib plus either giredestrant or anastrozole for ER-positive, HER2-negative early breast cancer

The development of more potent selective estrogen receptor antagonists and degraders (SERDs) that can be orally administered could help address the limitations of current endocrine therapies. The multinational phase 2 coopERA Breast Cancer study found that among patients with ER-positive, HER2-negative early breast cancer, the non-steroidal oral SERD giresdestrant offered encouraging anti-proliferative and anti-tumor activity and was well tolerated, both as single agent and in combination with palbociclib.